Artificial intelligence is dramatically speeding up drug development — and a proprietary survey shows how it's priming a ...

A drug already safe for humans reduces disease-linked early features of Alzheimer’s in a lab model of the disease, say ...

Drug companies have quietly stepped back from development programs in long COVID and related conditions, leaving patients ...

The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...

New mid-stage data from Biogen’s Ionis-partnered therapy diranersen served to both validate the tau hypothesis in Alzheimer’s ...

There has been much discussion recently about how artificial intelligence and machine learning (AI/ML) will revolutionize pharmaceutical research. Substantial progress has been made in the discovery ...

In this New Scientist CoLab podcast, experts from global life sciences leader Cytiva explain the hidden, high-stakes science of purification that is required to close the gap between drug discovery ...

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced a ...

Kivo reports that over half of new FDA-approved drugs are now for rare diseases, thanks to the Orphan Drug Act of 1983, which incentivized their development.

Halozyme Therapeutics (NASDAQ:HALO) has entered into a global collaboration and license agreement with Incyte (NASDAQ:INCY) ...

Some drugs may seem like they were named by throwing darts at the alphabet – but the process of drug naming is actually very intentional. In an interview with Fox News Digital, Dr. Dave Latshaw, CEO ...

Industries from semiconductors to fiber-optic cables stand to benefit from space research and manufacturing, but experts told CNBC that medicine could see the most immediate disruption. A flurry of ...